Open an account

Innate Pharma SA

IPHA · NYSE

$1.50+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.50

About IPHA

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company employs 164 full-time employees The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

Employees
164
Headquarters
Marseille, Paca
Listed
Oct 31, 2006
Sector
Health Care
Industry
Biotechnology
Website
innate-pharma.com

IPHA key statistics

Market cap
145.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
36.65K
Volume
11.92K
Open price
$1.50
High today
$1.52
Low today
$1.48
52 Week high
$2.71
52 Week low
$1.17

Innate Pharma SA (IPHA) at a glance

As of Oct 23, 2026, Innate Pharma SA (IPHA) shares are priced at $1.50, giving the company a market cap of 145.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.48 and $1.52. The current price is 1.7% above the day's low and 1.3% below its high.

Volume so far is 11.92K shares, below the average of 36.65K shares a day.

Over the past year Innate Pharma SA has ranged from $1.17 to $2.71, and now sits 21% of the way up that range.

Innate Pharma SA met or beat analyst EPS estimates in 0 of the last 3 quarters. In Q2 FY26 it reported -$0.34 per share against an estimate of -$0.0707.

IPHA earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 3 quarters.

  1. Q2 FY19: reported $0.20 per share against an estimate of $0.3232
  2. Q1 FY26: reported -$0.55 per share against an estimate of -$0.1616
  3. Q2 FY26: reported -$0.34 per share against an estimate of -$0.0707

IPHA news

  • Press releaseBusiness Wire

    Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

  • Press releaseBusiness Wire

    Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

  • Press releaseBusiness Wire

    Innate Pharma Reports First Half 2026 Business Update and Financial Results

  • Press releaseBusiness Wire

    Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

  • Press releaseBusiness Wire

    Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

  • Press releaseBusiness Wire

    Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseBusiness Wire

    Innate Pharma Announces Conference Call and Webcast

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.